Management of Chronic Kidney Disease Stages 1–3- The prevalence of chronic kidney disease in the United States is rising for every stage of chronic kidney disease (CKD). CKD is associated with a number of adverse outcomes, including increased risk for mortality, cardiovascular disease, end stage renal disease, bone loss and fractures, infections, cognitive impairment, and frailty. Treatment of nonprimary CKD is often not directed at the CKD, but rather at underlying conditions or cardiovascular risk factors, such as hypertension or diabetes. Treatments may include blood pressure lowering medications, such as angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB), or other nonspecific therapies and other nonpharmacological interventions targeted, for example, at blood pressure control, glycemic control, cholesterol control, and obesity treatment.
This continuing medical education activity covers data from a systematic review of existing research that was conducted by the Minnesota Evidence-based Practice Center to evaluate the level of evidence currently available regarding screening, monitoring, and treatments for CKD, stages 1–3. It provides an overview of the comparative benefits and adverse effects of interventions for CKD, stages 1–3. This information is intended to inform patient care decisions by primary care practitioners.
Identify the benefits of medications and other interventions used as monotherapy or in combination for the treatment of chronic kidney disease, stages 1–3, with respect to the long-term outcomes of mortality and end-stage renal disease, as well as short-term vascular outcomes.
Identify the risks of adverse events resulting from interventions used as monotherapy or in combination for the treatment of chronic kidney disease, stages 1–3, with respect to the long-term outcomes of mortality and end-stage renal disease, as well as short-term vascular outcomes.1.0 Free AMA Pra CAT 1 CME for Physicians
Expires 10/31/15